Clinical Trial Update: Study Of Safety, Blood Levels, And Brain Receptor Occupancy Of GSK163090 Using PET Imaging In Healthy Males [Phase 1]

View source ↗

Summary

Phase 1 study assessing safety, plasma levels, and brain receptor occupancy of GSK163090 using PET in healthy male volunteers, with reference to depressive and …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anxiety Disorders
• Depressive Disorder

Drugs mentioned

• GSK163090

Snippet

Sponsor: GlaxoSmithKline | Conditions: Healthy Subjects, Depressive Disorder and Anxiety Disorders | Phase 1 | Status: COMPLETED